Biogen Idec has appointed Richard Rudick as VP of development sciences, value-based medicine.
He will lead the newly create value-based medicine group at Biogen Idec. This group focuses on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis.
Measuring the value of a new medicine is becoming increasingly important for pharma companies as healthcare systems look to assess the overall benefits to determine if it is suitable for reimbursement.
Rudick joins from Cleveland Clinic where he served as director of the Mellen Center for MS treatment and research for nearly 30 years.
“Through his years of hands-on clinical experience, he has gained a truly unique understanding of the needs of MS patients,” said Alfred Sandrock, chief medical officer of Biogen Idec. “His vision, expertise and passion bolsters our efforts to create real-world, practical solutions to empower better decision-making and improve the way people live with MS.”